A021101 Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Post-Operative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study
This research is being done to evaluate a new treatment program for patients with borderline resectable pancreas cancer. We want to find out what effects, good and bad, chemotherapy and chemoradiation have on your cancer and to see if it allows safe surgery.
Generally healthy adults with pancreatic cancer may be eligible to join if they also have the following conditions: * No prior chemotherapy or chemoradiation therapy; * No other cancer; * Females are not pregnant or nursing; * Normal laboratory test results.
Eligible subjects will receive 4 cycles of induction chemotherapy and undergo imaging assessments to determine the effect on their cancer. Subjects with adequate results will then receive a combination of chemotherapy while receiving radiation therapy. Subjects will then undergo imaging again to assess the effect on their cancer. If the subject is doing well, then they will proceed to surgery. Again, the subject will undergo imaging before receiving a final 2 courses of chemotherapy.
03/10/2014 04:02 AM